Completing the transition of Aleve and Femstat-3 brands from Procter & Gamble Co. to Roche and marketing partner Bayer Corp., advertising for the $35 million Femstat-3 account shifted to Euro RSCG Tatham from Leo Burnett
Co., both Chicago, and $70 million Aleve to BBDO
, Chicago, from D'Arcy Masius Benton & Bowles, New York. Also last week, Roche received FDA approval for prescription Femstat-1 with one-day treatment; however, Bristol-Myers Squibb Co. also won approval to market Vagistat-1 over the counter.
Copyright February 1997, Crain Communications Inc.